About InFo Hämatologie

InFo Hämatologie

InFo Hämatologie, published under the full title "InFo Hämatologie + Onkologie," is the German continuing-education journal for physicians working in oncology and hemato-oncology, published by Springer Medizin for the specialists confronting the blood cancers. The renowned CME magazine offers the news and information on all relevant topics of the oncology and hemato-oncology, presented clearly, factually, and utility-oriented for the practicing physicians. With its study reports, expert commentaries, CME and ASORS training, and congress highlights, it serves the hematologists and oncologists treating the blood and cancer diseases with the concise education their critical decisions demand.

Overview

InFo Hämatologie + Onkologie appears as the hemato-oncology's CME journal: the medium for the onkologisch tätige Ärztinnen und Ärzte, the hematologists, the oncologists, and the internists with the oncological focus who need the concise, practice-relevant continuing education alongside their clinical duties. The editorial program delivers the pregnant, practice-relevant CME that the busy physicians can complete; the study reports of the currently important publications from the international specialist journals, referiert concisely with the expert commentary of the outstanding studies placing them in the practice context; the CME and ASORS continuing education for the certified learning; the selected training series on the diagnostic, therapeutic, and supportive strategies in the oncology; and the current reports with the pointed highlights of the internationally relevant congresses, from the ASH to the ASCO to the German Cancer Congress.

The journal's volumes 12/2009 through 29/2026 document the continuous publication: the CME magazine that has educated the hemato-oncology for over 15 years without interruption. The bibliographic data: Print ISSN 2662-1754, electronic ISSN 2662-1762, journal ID 15004.

History

InFo Hämatologie + Onkologie grew from Springer Medizin's oncology portfolio: the publisher created the dedicated CME journal for the hemato-oncology, recognizing that the oncologically active physicians needed the concise, the current, and the certified education. The journal's development tracked the hemato-oncology's revolutions: the targeted therapies, the immunotherapies, the CAR-T cells, and the precision medicine transformed the blood-cancer treatment, and each wave created the education need that the journal fills.

The editorial voices include the evidence-based medicine advocates: Prof. Odette Wegwarth's editorials on the risk communication and the transparent information, calling for the revolution in the patient information, show the journal's commitment to the evidence. The journal's 2026 volume 29 documents the endurance: the CME magazine in its third decade.

Coverage and Content

The study-report coverage presents the currently important publications from the international journals: the trial results referiert concisely, with the expert commentary placing the outstanding studies in the practice context. The CME and ASORS training provides the certified education: the modules on the diagnostic, therapeutic, and supportive strategies that the physicians complete for their credits. The training series address the hemato-oncology's spectrum: from the leukemias to the lymphomas to the supportive care.

The congress coverage delivers the pointed highlights: the ASH, the ASCO, the EHA, and the German Cancer Congress (DKK) reported with the essential news. The risk-communication focus addresses the evidence: the survival rates' invalidity as the screening measure, the transparent information's revolution, and the informed decision's prerequisites. The journal's "klar, faktisch und nutzwertorientiert" (clear, factual, utility-oriented) style defines the presentation: no academic excess, no marketing gloss, just the applicable knowledge.

The Evidence-Based Voice

InFo Hämatologie's evidence-based voice, exemplified by Prof. Odette Wegwarth's editorials, distinguishes the journal: the Heisenberg Professor for medical risk competence and evidence-based decision-making at the Charité uses the journal to advocate the transparent information revolution. Her editorials dissect the deceptive numbers: the survival rates in the early-detection context as the invalid measure, the absolute mortality rates as the informative metric, and the informed decision as the goal, not the persuasion to participate.

This evidence-based commitment serves the readers: the hemato-oncologists who must communicate the risks and benefits to their patients need the risk competence that the journal teaches. The "Wir brauchen eine Revolution zur Förderung transparenter Informationen" (we need a revolution to promote transparent information) editorial encapsulates the mission: the journal doesn't just report the studies, it teaches the critical appraisal. In the oncology where the statistics can mislead and the marketing can oversell, the journal is the corrective: the medium that insists on the clear, the factual, and the utility-oriented, training the physicians to see through the deceptive numbers.

The Hemato-Oncology

InFo Hämatologie serves the hemato-oncology: the medicine of the blood diseases and the blood cancers, from the anemias to the leukemias, from the lymphomas to the multiple myeloma. The field's rapid advance, from the chemotherapy to the targeted agents to the cellular therapies, makes the continuous education essential: the hematologists must follow the trials, the approvals, and the guidelines.

The journal's CME focus serves the practicing physicians: the oncologically active doctors in the practices and the clinics need the certified education that fits their schedules, and the InFo Hämatologie delivers it concisely. The ASORS training addresses the specific qualification: the supportiv-oncology education. In the hemato-oncology where the progress is rapid and the decisions are critical, the journal is the education: the medium that keeps the physicians competent.

Organization and Ownership

InFo Hämatologie + Onkologie is published by the Springer Medizin Verlag GmbH, part of the Springer Nature group, within the publisher's extensive oncology and hematology portfolio. The journal's bibliographic data: Print ISSN 2662-1754, electronic ISSN 2662-1762. The editorial details beyond the publisher are not publicly confirmed in the available sources.

The business model is the medical-publishing model: the subscriptions from the physicians and the institutions who need the hemato-oncology CME, and the advertising from the pharmaceutical industry's oncology and hematology manufacturers, from the targeted-therapy producers to the immunotherapy makers to the cellular-therapy developers. The CME and ASORS certification adds the professional value: the physicians earn their required continuing-education credits through the journal's modules, making the subscription both the learning and the credential. The journal's 15-year continuity, from the volume 12/2009 to the 29/2026, documents the sustained demand: the hemato-oncology's rapid advance creates the permanent education need that the InFo Hämatologie fills, issue after issue.

Digital Presence

The springermedizin.de portal carries the journal digitally: the articles, the CME modules, and the archive, with the 2026 issues accessible online for the subscribers. The link.springer.com platform provides the citable articles with the DOIs: the editorials on the risk communication and the studies integrated into the scientific literature, discoverable through the Max Planck Institute's repositories and the citation databases. The digital formats extend the print's education: the physicians access the study reports on the devices, complete the CME and ASORS modules online for their credits, and follow the congress highlights between the issues.

For the hemato-oncology's physicians, InFo Hämatologie is the CME journal: the renowned continuing-education magazine with the study reports of the important international publications, the expert commentaries placing the outstanding studies in context, the CME and ASORS certified training, and the congress highlights from the ASH to the DKK, serving the oncology and hemato-oncology clearly, factually, and utility-oriented. In the field where the evidence determines the treatment and the statistics can deceive, the journal keeps the physicians current and critical: the news and information on all relevant topics, one issue at a time, for the patients with the blood and cancer diseases who deserve the informed decisions, today and tomorrow.